SPOTLIGHT -
Somerset, NJ-MedPointe Inc. has acquired all U.S. and Canadian rights to azelastine HCl (Optivar), a treatment for itching of the eye associated with allergic conjunctivitis in adults and children ages 3 and older.
ABVC BioPharma reaches global licensing deal for ophthalmology pipeline
EyePod: Modifier Gene Therapy: What is it?
Astellas receives permanent J-code for avacincaptad pegol intravitreal solution for GA
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
RadiusXR publishes NOVA clinical trial results for virtual reality perimetry
Belite Bio completes submission to PMDA to initiate Dragon II trial of Tinlarebant for the treatment of adolescent Stargardt disease in Japan